Related Experiment Videos
A long-term clinical experience with Lonidamine
Oncology
|January 1, 1984
Summary
Lonidamine (LNA) shows promise as a cancer treatment with fewer side effects than traditional chemotherapy. It demonstrated efficacy alone and enhanced other agents, particularly for advanced lung and brain tumors.
Area of Science:
- Oncology
- Pharmacology
Background:
- Lonidamine (LNA) is an investigational chemotherapeutic agent.
- LNA has been evaluated in advanced-stage cancers, both as monotherapy and in combination regimens.
- Standard chemotherapeutics often present significant toxicities.
Purpose of the Study:
- To assess the efficacy and safety profile of Lonidamine (LNA) in cancer treatment.
- To evaluate LNA's effectiveness as a standalone agent and its synergistic potential with other chemotherapeutic drugs.
Main Methods:
- Clinical investigation of Lonidamine (LNA) in patients with advanced-stage tumors.
- Evaluation of both acute and long-term treatment outcomes.
- Comparative analysis of LNA's side effect profile against conventional chemotherapy.
Main Results:
- Lonidamine (LNA) exhibited a distinct side effect profile, including myalgia, photosensitivity, and auditory changes, differing from typical chemotherapy adverse events.
- Monotherapy with LNA resulted in partial remission in one ovarian adenocarcinoma case and disease stabilization in two breast carcinoma and one microcytoma cases.
- Combination therapy demonstrated potentiated effects of chemotherapeutic agents, especially in treating brain metastases and lung adenocarcinomas.
Conclusions:
- Lonidamine (LNA) presents a favorable safety profile compared to conventional chemotherapeutic agents.
- LNA shows potential as an effective agent in specific advanced-stage cancers and as a potentiator of existing chemotherapies, particularly for challenging tumor types like brain metastases and lung adenocarcinomas.